Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
Roch Houot(Inserm), Ronald Levy(Hôpital Necker-Enfants Malades), Lieping Chen(Yale Cancer Center), Jack T. Lin(Stanford University), Jonathan M. Irish(Vanderbilt University), James A. Torchia(Dana-Farber Cancer Institute), Arne Kolstad(Oslo University Hospital), Holbrook E. Kohrt(Stanford University), June H. Myklebust(Oslo University Hospital), Matthew J. Goldstein(Stanford University), Ash A. Alizadeh(California Institute for Regenerative Medicine)
Cited by 135
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k